DVA - DaVita Q3 cash flow ops down 26% as growth stalls

DaVita (DVA) Q3 results:Revenues: $2,924.1M (+0.7%); Dialysis services: $2,781.7M (+0.2%).Net income: $158.7M (+10.7%); non-GAAP net income: $223.3M (-3.7%); EPS: $1.28 (+34.7%); non-GAAP EPS: $1.80 (+17.6%).Cash flow ops: $482.7M (-25.9%).Free cash flow from continuing ops: $286.8M (-43.4%).Dialysis treatments: 7,656,173 (+1.1%).Revenue negatively impacted by a decrease in commercial revenue per treatment, unfavorable changes in government payor mix and a decline in calcimimetics revenue per treatment, partially offset by increases in inpatient dialysis service revenue and Medicare rates due to the temporary suspension of Medicare sequestration.2020 guidance: Revenue: $11,500M - 11,600M from $11,500M - 11,700M; non-GAAP EPS: $7.35 - 7.60 from $6.25 - 6.75; free cash flow: $1,100M - 1,250M from $800M - 1,000M.Shares up a fraction after hours.DaVita HealthCare Partners EPS misses by $0.16, misses on revenue

For further details see:

DaVita Q3 cash flow ops down 26% as growth stalls